BrainsWay's Accelerated Deep TMS Protocol Receives Draft Coverage from Highmark Blue Cross Blue Shield

summarizeSummary

BrainsWay announced that Highmark Blue Cross Blue Shield has issued a draft medical policy to cover its accelerated Deep TMS protocol for adolescent and adult major depressive disorder, significantly expanding market access for the recently FDA-cleared treatment.

check_boxKey Events

• Draft Coverage Policy Issued

  Highmark Blue Cross Blue Shield released a draft medical policy to cover BrainsWay's accelerated Deep TMS™ protocol.

• Expanded Patient Population

  The draft policy extends coverage to both adolescent and adult patients with major depressive disorder (MDD).

• Accelerated Protocol Coverage

  The policy covers the SWIFT™ protocol, which offers a shorter, more flexible treatment course (38 sessions over 6 days acute + 4 weeks maintenance).

• Significant Payer Impact

  Highmark covers over seven million lives, representing a substantial market opportunity for BrainsWay.

auto_awesomeAnalysis

This development is highly positive for BrainsWay as it signals broader reimbursement for its recently FDA-cleared accelerated Deep TMS protocol. Highmark Blue Cross Blue Shield covers over seven million lives, making this a substantial market access expansion. The accelerated protocol, requiring fewer clinic visits, could drive increased adoption and revenue growth for the company. While currently a draft, the anticipated February 2026 effective date suggests strong progress towards formal adoption.